232 related articles for article (PubMed ID: 28739942)
1. Lipophilic siRNA targets albumin in situ and promotes bioavailability, tumor penetration, and carrier-free gene silencing.
Sarett SM; Werfel TA; Lee L; Jackson MA; Kilchrist KV; Brantley-Sieders D; Duvall CL
Proc Natl Acad Sci U S A; 2017 Aug; 114(32):E6490-E6497. PubMed ID: 28739942
[TBL] [Abstract][Full Text] [Related]
2. Hydrophobic interactions between polymeric carrier and palmitic acid-conjugated siRNA improve PEGylated polyplex stability and enhance in vivo pharmacokinetics and tumor gene silencing.
Sarett SM; Werfel TA; Chandra I; Jackson MA; Kavanaugh TE; Hattaway ME; Giorgio TD; Duvall CL
Biomaterials; 2016 Aug; 97():122-32. PubMed ID: 27163624
[TBL] [Abstract][Full Text] [Related]
3. An albumin-mediated cholesterol design-based strategy for tuning siRNA pharmacokinetics and gene silencing.
Bienk K; Hvam ML; Pakula MM; Dagnæs-Hansen F; Wengel J; Malle BM; Kragh-Hansen U; Cameron J; Bukrinski JT; Howard KA
J Control Release; 2016 Jun; 232():143-51. PubMed ID: 27084489
[TBL] [Abstract][Full Text] [Related]
4. Preparation and characterization of novel albumin-sericin nanoparticles as siRNA delivery vehicle for laryngeal cancer treatment.
Yalcin E; Kara G; Celik E; Pinarli FA; Saylam G; Sucularli C; Ozturk S; Yilmaz E; Bayir O; Korkmaz MH; Denkbas EB
Prep Biochem Biotechnol; 2019; 49(7):659-670. PubMed ID: 31066619
[TBL] [Abstract][Full Text] [Related]
5. Enhanced extravasation, stability and in vivo cardiac gene silencing via in situ siRNA-albumin conjugation.
Lau S; Graham B; Cao N; Boyd BJ; Pouton CW; White PJ
Mol Pharm; 2012 Jan; 9(1):71-80. PubMed ID: 22141328
[TBL] [Abstract][Full Text] [Related]
6. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
[TBL] [Abstract][Full Text] [Related]
7. Chemical modulation of siRNA lipophilicity for efficient delivery.
Tai W
J Control Release; 2019 Aug; 307():98-107. PubMed ID: 31229473
[TBL] [Abstract][Full Text] [Related]
8. Tumor Selective Silencing Using an RNAi-Conjugated Polymeric Nanopharmaceutical.
Svenson S; Case RI; Cole RO; Hwang J; Kabir SR; Lazarus D; Lim Soo P; Ng PS; Peters C; Shum P; Sweryda-Krawiec B; Tripathi S; van der Poll D; Eliasof S
Mol Pharm; 2016 Mar; 13(3):737-47. PubMed ID: 26835715
[TBL] [Abstract][Full Text] [Related]
9. Systemic delivery of stable siRNA-encapsulating lipid vesicles: optimization, biodistribution, and tumor suppression.
Dar GH; Gopal V; Rao NM
Mol Pharm; 2015 Feb; 12(2):610-20. PubMed ID: 25545110
[TBL] [Abstract][Full Text] [Related]
10. Structural optimization of siRNA conjugates for albumin binding achieves effective MCL1-directed cancer therapy.
Hoogenboezem EN; Patel SS; Lo JH; Cavnar AB; Babb LM; Francini N; Gbur EF; Patil P; Colazo JM; Michell DL; Sanchez VM; McCune JT; Ma J; DeJulius CR; Lee LH; Rosch JC; Allen RM; Stokes LD; Hill JL; Vickers KC; Cook RS; Duvall CL
Nat Commun; 2024 Feb; 15(1):1581. PubMed ID: 38383524
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic silence of pleiotrophin by targeted delivery of siRNA and its effect on the inhibition of tumor growth and metastasis.
Zha L; He L; Xie W; Cheng J; Li T; Mohsen MO; Lei F; Storni F; Bachmann M; Chen H; Zhang Y
PLoS One; 2017; 12(5):e0177964. PubMed ID: 28562667
[TBL] [Abstract][Full Text] [Related]
12. Conjugate Polyplexes with Anti-Invasive Properties and Improved siRNA Delivery In Vivo.
Chen Y; Li J; Oupický D
Bioconjug Chem; 2018 Feb; 29(2):296-305. PubMed ID: 29338191
[TBL] [Abstract][Full Text] [Related]
13. Characterization of long-circulating cationic nanoparticle formulations consisting of a two-stage PEGylation step for the delivery of siRNA in a breast cancer tumor model.
Ho EA; Osooly M; Strutt D; Masin D; Yang Y; Yan H; Bally M
J Pharm Sci; 2013 Jan; 102(1):227-36. PubMed ID: 23132529
[TBL] [Abstract][Full Text] [Related]
14. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
Varshosaz J; Farzan M
World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
[TBL] [Abstract][Full Text] [Related]
15. Design of Highly Potent Lipid-Functionalized Peptidomimetics for Efficient in Vivo siRNA Delivery.
Xiao H; Altangerel A; Gerile G; Wu Y; Baigude H
ACS Appl Mater Interfaces; 2016 Mar; 8(12):7638-45. PubMed ID: 26964858
[TBL] [Abstract][Full Text] [Related]
16. Structural Optimization of siRNA Conjugates for Albumin Binding Achieves Effective MCL1-Targeted Cancer Therapy.
Hoogenboezem EN; Patel SS; Cavnar AB; Lo JH; Babb LM; Francini N; Patil P; Colazo JM; Michell DL; Sanchez VM; McCune JT; Ma J; DeJulius CR; Lee LH; Rosch JC; Allen RM; Stokes LD; Hill JL; Vickers KC; Cook RS; Duvall CL
bioRxiv; 2023 Feb; ():. PubMed ID: 36824780
[TBL] [Abstract][Full Text] [Related]
17. In vivo delivery of small interfering RNA to tumors and their vasculature by novel dendritic nanocarriers.
Ofek P; Fischer W; Calderón M; Haag R; Satchi-Fainaro R
FASEB J; 2010 Sep; 24(9):3122-34. PubMed ID: 20385622
[TBL] [Abstract][Full Text] [Related]
18. Dual carrier-cargo hydrophobization and charge ratio optimization improve the systemic circulation and safety of zwitterionic nano-polyplexes.
Jackson MA; Bedingfield SK; Yu F; Stokan ME; Miles RE; Curvino EJ; Hoogenboezem EN; Bonami RH; Patel SS; Kendall PL; Giorgio TD; Duvall CL
Biomaterials; 2019 Feb; 192():245-259. PubMed ID: 30458360
[TBL] [Abstract][Full Text] [Related]
19. Surface-modified HK:siRNA nanoplexes with enhanced pharmacokinetics and tumor growth inhibition.
Chou ST; Leng Q; Scaria P; Kahn JD; Tricoli LJ; Woodle M; Mixson AJ
Biomacromolecules; 2013 Mar; 14(3):752-60. PubMed ID: 23360232
[TBL] [Abstract][Full Text] [Related]
20. Tumoral gene silencing by receptor-targeted combinatorial siRNA polyplexes.
Lee DJ; He D; Kessel E; Padari K; Kempter S; Lächelt U; Rädler JO; Pooga M; Wagner E
J Control Release; 2016 Dec; 244(Pt B):280-291. PubMed ID: 27287890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
